Zydus Announces Partnership with Takeda for Vault® (Vonoprazan) in India

Zydus Lifesciences Limited announced in a stock exchange filing that it has entered a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company.

The agreement is to market Vonoprazan, a novel Potassium Competitive Acid Blocker (P-CAB), in India under the brand name Vault®. This agreement aims to address the significant prevalence of Gastroesophageal Reflux Disease (GERD) in India, estimated at 15.6% of the population, according to a 2021 study in the Indian Journal of Gastroenterology.

Zydus has a history of introducing pioneering treatments for GERD in India, including Pantodac® (Pantoprazole), Happi® (Rabeprazole), and Ocid® (Omeprazole), and notably launched Pantoprazole in 1999.

Vonoprazan works uniquely by inhibiting the binding of potassium ions to the proton pump in stomach cells, effectively reducing both basal and stimulated gastric acid secretion. The Drug Controller General of India (DCGI) has approved Vonoprazan for treating adults with Reflux esophagitis and other Acid Peptic Disorders (APD), expanding treatment options for clinicians managing these conditions.

The introduction of Vault® (Vonoprazan) represents a significant advancement in GERD treatment in India, offering healthcare providers and patients a new therapeutic option that complements existing treatments. This strategic move underscores Zydus’ commitment to enhancing healthcare outcomes by bringing innovative therapies to the Indian market.

Commenting on this significant development, the Managing Director of Zydus Lifesciences Ltd, Dr Sharvil Patel, said, “With a rich legacy in marketing gastrointestinal therapies in India, we have been offering different breakthrough clinical options across the spectrum. In keeping with our patient-centric approaches, we have been enabling access to newer treatment options and innovative healthcare solutions for nearly three decades. We are happy to add Vault® to our wide basket of gastro-therapeutic products and widen our range of treatments for acid peptic disorders.”

On July 18, 2024, the share price of Zydus Lifesciences Limited opened at ₹1,186.00, touching the day’s low at ₹1,167.00, as of 10:39 AM on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.